Abstract:Background According to the reports, the most vital characteristic of obesity is an aberrant accumulation of triglycerides (TG) in the adipocyte. On the other hand, circulating concentrations of apolipoprotein A1 (apoA1) have been demonstrated to be strongly correlated with the prevalence and the pathological development of obesity. Nevertheless, the underlying mechanisms whereby apoA1 modulates the pathogenesis of obesity is still not fully elucidated. Methods Adipose-derived mesenchymal stem cells (AMSCs, isolated from the hospitalized patients were combined with 15 & mu;g/ml recombined human apoA1 protein. The effects of apoA1 on modulating the intracellular levels of TG and the expression contents of adipogenic related cytokines were also analyzed. Furthermore, whether apoA1 modulated the adipogenesis progression via sortilin was also explored in the current research. Results During the adipogenesis progression, apoA1 could significantly lower the quantity of intracellular lipid droplets (LDs). Meanwhile, apoA1 could decrease the intracellular levels of TG and down-regulate the expression contents of several vital adipogenic related cytokines, such as CCAAT enhancer-binding proteins & alpha;/& beta; (C/EBP & alpha;/& beta;), fatty acid synthetase (FAS), and fatty acid-binding protein 4 (FABP4). Moreover, the inhibitory effect of apoA1 was further verified to be induced through up-regulating the SORT1 gene expression which subsequently increased sortilin protein. Consistent with these findings, silencing the SORT1 gene expression could induce the loss-of-function (LOF) of apoA1 in modulating the adipogenesis progression of AMSCs. Conclusion In conclusion, apoA1 could suppress the adipogenesis progression of human AMSCs through, at least partly, up-regulating the SORT1 gene expression which subsequently increases the sortilin protein content. Thereby, the present research sheds light on a novel pathogenic mechanism by which apoA1 regulates adipogenesis progression and proposes that apoA1 embraces the function to treat obesity in clinical practice.

Apelin Inhibits Adipogenesis and Lipolysis Through Distinct Molecular Pathways

Apelin decreases lipolysis via G(q), G(i), and AMPK-Dependent Mechanisms

Apelin Plays A Catabolic Role On Articular Cartilage: In Vivo And In Vitro Studies

Apelin-13 Impedes Foam Cell Formation by Activating Class Iii Pi3k/Beclin-1-Mediated Autophagic Pathway

Apelin Protects Against Liver X Receptor-Mediated Steatosis Through AMPK and PPARα in Human and Mouse Hepatocytes.

Correction: Apelin Ameliorates TNF-α-Induced Reduction of Glycogen Synthesis in the Hepatocytes Through G Protein-Coupled Receptor APJ

Function of Apelin in Cardiovascular System and Adipoinsular Axis

Adipokine apelin and diabetes

Apelin Suppresses Apoptosis of Human Osteoblasts

Regulation of Apelin-13 on Bcl-2 and Caspase-3 and Its Effects on Adipocyte Apoptosis

Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction

Apelin/APJ system as a therapeutic target in diabetes and its complications.

Apelin–APJ Induces ICAM-1, VCAM-1 and MCP-1 Expression Via NF-κB/JNK Signal Pathway in Human Umbilical Vein Endothelial Cells

Apelin-13 Inhibits Lipid Accumulation in Human Hepatocytes

Apelin/APJ System As a Therapeutic Target in Diabetes and Its Complications

Apelin-13 Increases Expression of ATP-binding Cassette Transporter A1 Via Activating Protein Kinase C Α Signaling in THP-1 Macrophage-Derived Foam Cells.

Annexin A1 binds PDZ and LIM domain 7 to inhibit adipogenesis and prevent obesity

Apelin-36 Modulates Blood Glucose and Body Weight Independently of Canonical APJ Receptor Signaling

Endothelial APLNR Regulates Tissue Fatty Acid Uptake and is Essential for Apelin's Glucose-Lowering Effects.

Apelin and insulin resistance: Another arrow for the quiver?

Apolipoprotein A1 Inhibits Adipogenesis Progression of Human Adipose-Derived Mesenchymal Stem Cells